A SAS Application for Analyzing Quality of Life data: NCIC-CTG Standard Method
|
|
- Judith Hood
- 5 years ago
- Views:
Transcription
1 Paper SP01 A SAS Application for Analyzing Quality of Life data: NCIC-CTG Standard Method Don (Dongguang) Li, NCIC-CTG, Queen s University, Kingston, ON, Canada ABSTRACT The Health-Related Quality of Life (HRQOL) measurements have been frequently applied in clinical trials of chronic diseases (such as cancers). There are many measurement tools of HRQOL questionnaires and diverse statistical analysis methods accordingly, which make the analysis of HRQOL data rather complicated and hard to be standardized. This article provides a SAS macro application based on the standard method of HRQOL data analysis of the National Cancer Institute Clinical Trials Group (NCIN-CTG) [1] The program integrates data manipulation, statistical analyses and reports generation processes. It can calculate HRQOL domains from different measurement tools, determine visit/cycle through predefined time windows and summarize the HRQOL domains response rates. The analysis results are organized into standard statistical reports, which includes the compliance rates, baseline scores comparison, the analysis of the changes of the domain scores from baseline and the summary responses analysis results. The strategies and the kernel program codes are discussed. KEY WORDS Health-related Quality of Life (HRQOL), Statistical analysis, SAS macros INTRODUCTION As the usage of HRQOL data analysis in clinical trials becomes more and more frequent, the statistical methodologies and questionnaire tools have been developed rapidly. Some complex analysis methods were criticized for the difficulties in modeling and in results interpreting [2]. A method emphasizing the clinical meaning while avoiding complex statistical modeling is desired by clinicians and other non-statistics researchers. The National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG) has been carrying out HRQOL assessments since From the plentiful experiences, NCIC-CTG has developed an approach that focuses on the clinical interpretation with a summary response (improved, stable and worsened). This approach consists of four standard steps: Calculating the compliance rates, comparing baseline scores between groups, comparing the changes of the scores from baseline, and compare the proportion of responses between the treatment groups [1]. Following this standard procedure, a SAS macro application is developed to perform the analyses. STATISTICAL ANALYSIS METHODS The baseline scores comparison uses non-parametric (the Wilcoxon Rank-sum) test. It supposes no statistically significant difference between the treatment groups; otherwise the validity of randomization will be challenged. The parametric test (comparing mean score-changes) is suggested in comparing score-changes, because it has been found that there is little practical difference between using non-parametric and parametric approaches (unpublished data). There are many approaches determining the summary response [3]. A 10% cut-off scale is recommended by NCIC- CTG standard approach, but the scale can vary according to the specific trials. If the scores exceed the cut-off scale in the defined study period, the response is classified as Improved ; while scores decline below the scale in the study period, the response is classified as Worsened. The situation that is neither improved nor worsened is classified as Stable. The Chi-square test is used to analyze the difference of the response rates between the treatment groups. PROGRAMMING STRATEGIES Although the statistical analyses methods are straightforward, there are several crucial points in the programming. First, there is usually no cycle/visit information in the HRQOL questionnaire and the cycle needs to be determined with the predefined time window. Second, the designed analyses will be conducted for all the domains. This needs looping the analyses to all domains. Third, the logic of classifying the response categories is the key part of the program. The program will detect the QOL score changes and define the response categories. Fourth, if trial specific questions/domains are used, it is hard to automatically include them into the macro application. Moreover, the domains calculation from different questionnaire tools is hard to be automated because so many forms are available and may be used.
2 To accommodate these crucial points, the following strategies are considered in the SAS programming: 1. Divide the analyses into functional modules. The modules include domain calculation, data preparation, compliance rates calculation and reporting, baseline score comparison, score-changes comparison, and response rate comparison. The cycle determination and response classification are included in the data preparation step. 2. Use a macro parameter entry to control the time window, as it might be study dependent. Specific coding may be necessary if the follow-up time is not designed in an equal period. 3. Keep the names of all the domains with the contents procedure and convert them to a macro variable array. Use do-loop to repeat the analyses on each of the domains. 4. Create the domain calculation program based on the specific questionnaire tools. So far we have programs for several most commonly used QOL tools in cancer clinical trials (EORTC30, EORTC13, SF36 and combined EORTC). More programs can be added if other alternative questionnaire tools are used and the assessment methods are provided. 5. For the extra trial specific domains, a macro string is defined in the macro parameter entries. The string lists extra domain names and will be used as an array in the data preparing step. 6. Use the logic conditions to classify the response. If the score changes reach the upper boundary it id defined as Improved ; otherwise, if the score changes reach the lower boundary it is defined as Worsened ; for the rest situations the response is defined as Stable. 7. Use standard templates to generate all the reports and save them to output files. EXAMPLES OF THE KERNEL SAS CODES The example codes for some of the key issues are shown and discussed as below. Domains calculation: QOL domains calculation is measurement tools specific. Most of the QOL questions use four or seven categories recording the patients answer on the QOL questions. Generally, the categorical scores are converted into a 100- based scale number. The calculations for functional domains and symptom domains are different. For example, in EORTC30: *** domain parameter calculation***; *** physical(functional domain)***; nm=nmiss(of q_1-q_5); if nm>2 then phys=.; else do; sum=sum(q_1,q_2,q_3,q_4,q_5); phys=100-((sum/(5-nm)-1)*100/3); *** Fatigue (symptom domain) ***; nm=nmiss(q_10,q_12,q_18); if nm>1 then fati=.; else do sum=sum(q_10,q_12,q_18); fati=((sum/(3-nm)-1)*100/3); For example if the answers for question 10, 12 and 18 are 2, 3, and 3, the converted domain score for fatigue will be Determining cycles with time window The time window is defined as a macro variable (for example, 7 days for treatment cycles). There may be different time windows for follow-up (for example, 30 days). The difference in days between the date the questionnaire is filledout and the treatment date for the cycle is calculated. If it falls within the time window, the HRQOL data belongs to the same treatment cycle/follow-up. The total number of cycles / follow-ups can be determined in the data step. The code below is the example of combining QOL and treatment data:
3 *** determine cycle no for qol ***; %do i=1 %to &cno; data qolf&i; length time $2; merge qol form3(where=(cycle=&i) in=a); by id; if a; diff=qol_dt-chem_dt; /*window adjust*/ if (-&cwd <= diff <= &cwd) then time=compbl("c&i"); output; Where macro variable &cno is the total number of cycles and &cwd is the value of time window. The new variable time is the cycle variable assigned to HRQOL data. Now All QOL records that fall into the time window find their cycles. Follow-up QOL data can be handled in the same way. data qolf&i; set qolf&i; where time="c&i"; drop cycle; % *** pool data by cycle ***; data qolfm3; set %do i=1 %to &cno; qolf&i % ; Classifying the QOL response As described above, the response is classified as Improved, Worsened and Stable. The program code firstly checks if the scores can be defined as Improved based on the score changing criteria. If so, the response is Improved even if the scores are somewhere below the lower-boundary. If it is not improved, the program checks if the response is Worsened. Finally, if neither Improved nor Worsened the response is classified as Stable. In the program code (see textbox at the right side), &varno is the number of domain variables. The macro variable &fdm is a predetermined string of all functional domain names. The program merges the cycle / followup QOL data and the baseline QOL data, and calculates the score changes. The determination of responses is different for functional and symptom domains. The response classification is performed to each domain by looping. The program gives the improved cases the value of 3 and the worsened and Stable cases 2 and 1, respectively. The largest value is kept to ensure the priority of improved cases. After this step, the responses are changed back to 1 (improved), 0 (stable) and 1 (worsened) for standard analysis. *** Define response by cut-off ***; %do i=1 %to &varno; data chng&i; merge qolfol(keep=id time allo1_cd &&q&i) bsline(keep=id s&&q&i); by id; domain=trim(left("&&q&i")); *** Do differently for F- and S-domains ***; if domain in (&fdm) then do; if &&q&i-s&&q&i>=10 then d&&q&i=3 ; else if 10>&&q&i-s&&q&i>-10 then d&&q&i=1 ; else if.<&&q&i-s&&q&i<=-10 then d&&q&i=2; else do; if &&q&i-s&&q&i>=10 then d&&q&i=2 ; else if 10>&&q&i-s&&q&i>-10 then d&&q&i=1 ; else if.<&&q&i-s&&q&i<=-10 then d&&q&i=3; proc sort; by id d&&q&i; data chng&i; set chng&i; by id d&&q&i; if last.id; /* keep the largest d&&q&i*/ if d&&q&i=3 then d&&q&i=1; else if d&&q&i=2 then d&&q&i=-1; else if d&&q&i=1 then d&&q&i=0; drop domain &&q&i s&&q&i ;
4 SELECTED REPORT EXAMPLES Compliance table: NCIC-CTG TRIAL XX00 Table #: Compliance (Received/Eligible) with QOL Assessment by Treatment Arm TREATMENT A TREATMENT B Period Eligible Received (%) Eligible Received (%) Baseline (90.8) (82.2) Cycle (85.0) (80.9) Cycle (60.1) (67.8) Cycle (52.9) (55.3) Cycle (43.8) (45.4) Cycle (35.9) (38.8) Cycle (30.7) (31.6) Cycle (0.7) 152 2(1.3) Month (39.2) (40.8) Month (20.3) (15.8) Month (9.2) 152 9(5.9) Month (5.9) 152 5(3.3) Month (6.5) 152 4(2.6) Month (2.6) 152 3(2.0) Month (1.3) 152 3(2.0) Month (0.7) 152 2(1.3) Only part of the compliance and response analyses tables are shown as examples. The reports of cross-sectional analysis by cycle/follow-up and of baseline score test are not shown here. The baseline score test displays the mean values of all QOL domains by treatment group with the test p-values. The cross- sectional comparison shows the similar results (mean domain values by treatment with test p-values) for each of the treatment cycle and follow-up. DISCUSSION HRQOL data analysis is a common practice in cancer clinical trials. Standard analysis approaches and corresponding analysis applications are required. The NCIC-CTG s standard analysis approach provides the basis for building up a robust analysis system of analyzing the HRQOL data. The NCIC-CTG s approach is simple and straightforward in statistical methodology. The data management procedures are standard. These facts make it possible to used SAS macro based programs to automate the analysis steps. The difficulties in defining cycles, determining response and repeating the analyses for all the domain variables can be concurred with the SAS programming techniques. The SAS application introduced in this article is still in its primary stage. The most important pre-requisite is that the structure and contents of the clinical datasets should be relatively standard. For example, the QOL variables should be named in the same manner (Q_1-Q_## for question number, qol_dt for the date when the HRQOL questionnaire is filled out, and so on); the dataset name and contents should also be standard (F1data for baseline, F3data for treatment, F5data for follow-up etc.). If the data structure and contents are not in the standard format, an extra step is needed to modify the datasets into the pattern that meets the requirements of the SAS application. A specific format section may be needed too, to apply the format for domain names, response levels and cycle / follow-up descriptions. There might be concerns that the NCIC-CTG standard QOL data analysis approach summarizes the response only based on one point and it may result in losing information of all the time period. Our ongoing study revealed that there is well consistency of the result of this method with the results of more complicated statistical modeling. This article is not purposed to compare statistical methodologies.
5 QOL response rates analysis NCIC-CTG TRIAL XX00 Table #: Results for QOL Response Analyses TREATMENT A TREATMENT B N (%) N (%) Domain/item Improved Stable Worsened Improved Stable Worsened P value* Physical 23(12.50) 34(18.48) 40(21.74) 27(14.67) 25(13.59) 35(19.02) Role 44(18.80) 15( 6.41) 62(26.50) 50(21.37) 19( 8.12) 44(18.80) Emotional 61(25.00) 31(12.70) 35(14.34) 66(27.05) 28(11.48) 23( 9.43) Cognitive 48(19.83) 27(11.16) 51(21.07) 51(21.07) 31(12.81) 34(14.05) Social 48(20.08) 19( 7.95) 58(24.27) 39(16.32) 30(12.55) 45(18.83) Fatigue 60(24.79) 11( 4.55) 55(22.73) 57(23.55) 18( 7.44) 41(16.94) Nausea 24( 9.92) 46(19.01) 55(22.73) 29(11.98) 27(11.16) 61(25.21) Pain 58(24.68) 26(11.06) 38(16.17) 66(28.09) 19( 8.09) 28(11.91) Dyspnea 37(15.42) 52(21.67) 36(15.00) 36(15.00) 43(17.92) 36(15.00) Sleep 57(23.85) 30(12.55) 37(15.48) 51(21.34) 37(15.48) 27(11.30) Appetite 34(14.11) 28(11.62) 63(26.14) 36(14.94) 33(13.69) 47(19.50) Constipation 39(16.12) 42(17.36) 44(18.18) 30(12.40) 48(19.83) 39(16.12) Diarrhea 10( 4.12) 91(37.45) 25(10.29) 13( 5.35) 75(30.86) 29(11.93) Financial 37(15.35) 48(19.92) 40(16.60) 33(13.69) 56(23.24) 27(11.20) Global 57(23.95) 33(13.87) 34(14.29) 47(19.75) 33(13.87) 34(14.29) Body 33(13.64) 30(12.40) 63(26.03) 41(16.94) 31(12.81) 44(18.18) (More ) CONCLUSION This article introduces the NICI-CTG standard HRQOL data analysis approach and a SAS macro oriented analysis application based on the approach. The programming strategies are discussed. For the key technical issues in data managing and analyzing, solutions with SAS programming techniques are provided. The example codes of some substantial steps are included, too. This application can be a model of automating the data analysis processes with a standard data analysis approach. REFERENCES 1. Osoba D, et al: Analysis and Reporting of Health-related Quality of Life Data from Clinical Trials: An approach of the National Cancer Institute of Canada Clinical Trials Group (unpublished). 2. Gill TM, Feinstein AR: A critical appraisal of the quality of quality-of-life measurements. J Am Med Assoc 272: , Langendijk JA, Aaronson NK, de Jong JMA, et al: Prospective study on quality of life before and after radical radiotherapy in non-small-cell lung cancer. J Clin Oncol 19: , 2001 CONTACT INFORMATION Don (Dongguang) Li, PhD, MPH, Senior Biostatistician National Cancer Institute of Canada - Clinical Trials Group 10 Stuart Street, Queen s University, Kingston, Canada, K7L 3N Ext dli@ctg.queensu.ca
EORTC QLQ-C30 descriptive analysis with the qlqc30 command
The Stata Journal (2015) 15, Number 4, pp. 1060 1074 EORTC QLQ-C30 descriptive analysis with the qlqc30 command Caroline Bascoul-Mollevi Biostatistics Unit CTD INCa, Institut régional du Cancer de Montpellier
More informationA Gynecologic Cancer Intergroup Study of the NCIC Clinical Trials Group (NCIC CTG), the European Organization for Research and
Randomized study of sequential cisplatintopotecan/carboplatin-paclitaxel versus carboplatin-paclitaxel: effects on quality of life A Gynecologic Cancer Intergroup Study of the NCIC Clinical Trials Group
More informationApplications of Quality of Life Outcomes in Three Recent NCIC CTG Trials: What Every New Clinician-Investigator Wants to Know
Workshop # 5 Applications of Quality of Life Outcomes in Three Recent NCIC CTG Trials: What Every New Clinician-Investigator Wants to Know M. Brundage and H. Richardson Outline Nature of QOL data a brief
More informationBackground. 2 5/30/2017 Company Confidential 2015 Eli Lilly and Company
May 2017 Estimating the effects of patient-reported outcome (PRO) diarrhea and pain measures on PRO fatigue: data analysis from a phase 2 study of abemaciclib monotherapy, a CDK4 and CDK6 inhibitor, in
More informationIntro to SPSS. Using SPSS through WebFAS
Intro to SPSS Using SPSS through WebFAS http://www.yorku.ca/computing/students/labs/webfas/ Try it early (make sure it works from your computer) If you need help contact UIT Client Services Voice: 416-736-5800
More informationA SAS sy Study of ediary Data
A SAS sy Study of ediary Data ABSTRACT PharmaSUG 2017 - Paper BB14 A SAS sy Study of ediary Data Amie Bissonett, inventiv Health Clinical, Minneapolis, MN Many sponsors are using electronic diaries (ediaries)
More informationProgrammatic Challenges of Dose Tapering Using SAS
ABSTRACT: Paper 2036-2014 Programmatic Challenges of Dose Tapering Using SAS Iuliana Barbalau, Santen Inc., Emeryville, CA Chen Shi, Santen Inc., Emeryville, CA Yang Yang, Santen Inc., Emeryville, CA In
More informationJ Clin Oncol 24: by American Society of Clinical Oncology INTRODUCTION
VOLUME 24 NUMBER 24 AUGUST 20 2006 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Symptom Improvement in Lung Cancer Patients Treated With Erlotinib: Quality of Life Analysis of the National
More informationIntroducing the QLU-C10D A preference-based utility measure derived from the QLQ-C30
Introducing the QLU-C10D A preference-based utility measure derived from the QLQ-C30 Presented by Professor Madeleine King Cancer Australia Chair in Cancer Quality of Life Faculties of Science and Medicine
More informationOriginal Article on Palliative Radiotherapy
Original Article on Palliative Radiotherapy Quality of life in responders after palliative radiation therapy for painful bone metastases using EORTC QLQ-C30 and EORTC QLQ- BM22: results of a Brazilian
More informationImplementing Patient Report Outcome Data in Clinical Trials Analysis
PharmaSUG 2017 - Paper PO04 Implementing Patient Report Outcome Data in Clinical Trials Analysis ABSTRACT Qi Wang, Amgen, Thousand Oaks, CA Over the recent decades, Health-Related Quality of Life (HRQoL)
More informationPRO ASSESSMENT IN CANCER TRIALS. Emiliano Calvo, Anita Margulies, Eric Raymond, Ian Tannock, Nadia Harbeck and Lonneke van de Poll-Franse
PRO ASSESSMENT IN CANCER TRIALS Emiliano Calvo, Anita Margulies, Eric Raymond, Ian Tannock, Nadia Harbeck and Lonneke van de Poll-Franse DISCLOSURES Emiliano Calvo has reported no conflicts of interest
More informationUvA-DARE (Digital Academic Repository)
UvA-DARE (Digital Academic Repository) Modification of the EORTC QLQ-C30 (version 2.0) based on content valdity and reliability testing in large samples of patients with cancer Osoba, D.; Aaronson, N.K.;
More informationMapping the EORTC QLQ C-30 onto the EQ-5D Instrument: The Potential to Estimate QALYs without Generic Preference Data
Volume 12 Number 1 2009 VALUE IN HEALTH Mapping the EORTC QLQ C-30 onto the EQ-5D Instrument: The Potential to Estimate QALYs without Generic Preference Data Lynda McKenzie, MSc, Marjon van der Pol, PhD
More informationSession 6: Choosing and using HRQoL measures vs Multi-Attribute Utility Instruments QLU-C10D and EQ-5D as examples
Session 6: Choosing and using HRQoL measures vs Multi-Attribute Utility Instruments QLU-C10D and EQ-5D as examples - Madeleine King & Richard De Abreu Lourenco- Overview Learning Objectives To discuss
More informationHealth Technology Assessment (HTA)
Health Technology Assessment (HTA) Determination of utilities for the QLQ-C30 Georg Kemmler, Eva Gamper, Bernhard Holzner Department for Psychiatry and Psychotherapy Innsbruck Medical University Austria
More informationQuality of Life in Patients with Chronic Myeloid Leukemia
Quality of Life in Patients with Chronic Myeloid Leukemia Fabio Efficace, PhD Chairman GIMEMA WP Quality of Life Head, Health Outcomes Research Unit Italian Group for Adult Hematologic Diseases (GIMEMA)
More information10th anniversary of 1st validated CaPspecific
Quality of Life after Treatment of Localised Prostate Cancer Dr Jeremy Grummet Clinical Uro-Oncology Fellow May 28, 2008 1 Why? This is important May be viewed as soft science Until we know which treatment
More informationStata: Merge and append Topics: Merging datasets, appending datasets - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - 1. Terms There are several situations when working with
More informationAuthor's response to reviews
Author's response to reviews Title: Evaluation of Safety and Efficacy of Gefitinib ('Iressa', ZD1839) as Monotherapy in a series of Chinese Patients with Advanced Non-small-cell Lung Cancer: Experience
More informationMOBILE PATIENT-REPORTED OUTCOME (PRO) ASSESSMENT TO DRIVE ADHERENCE
MOBILE PATIENT-REPORTED OUTCOME (PRO) ASSESSMENT TO DRIVE ADHERENCE Heather Jim, PhD Moffitt Cancer Center heather.jim@moffitt.org There are no conflicts to disclose LEARNING OBJECTIVES After reading and
More informationAnnals of Oncology Advance Access published January 30, 2012
Advance Access published January 30, 2012 original article doi:10.1093/annonc/mdr583 Health-related quality of life in recurrent platinum-sensitive ovarian cancer results from the CALYPSO trial M. Brundage
More informationQOL Improvements in NETTER-1 Phase III Trial in Patients With Progressive Midgut Neuroendocrine Tumors
QOL Improvements in NETTER-1 Phase III Trial in Patients With Progressive Midgut Neuroendocrine Tumors Abstract C-33 Strosberg J, Wolin E, Chasen B, Kulke M, Bushnell D, Caplin M, Baum RP, Kunz P, Hobday
More informationHealth-Related Quality of Life in Brain Tumor Patients Treated with Surgery: Preliminary Result of a Single Institution
ORIGINAL ARTICLE Brain Tumor Res Treat 2016;4(2):87-93 / pissn 2288-2405 / eissn 2288-2413 http://dx.doi.org/10.14791/btrt.2016.4.2.87 Health-Related Quality of Life in Brain Tumor Patients Treated with
More informationAllergan Not Applicable AGN A Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Multiple Dose, Parallel
Peripheral Neuropathy Design, Dose Ranging Study of the Safety and Efficacy of AGN 203818 in Patients with Painful Diabetic 203818-004. A Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Multiple
More informationReliability and Validity of the Taiwan Chinese Version of the EORTC QLQ-PR25 in Assessing Quality of Life of Prostate Cancer Patients
Urol Sci 2010;21(3):118 125 ORIGINAL ARTICLE Reliability and Validity of the Taiwan Chinese Version of the EORTC QLQ-PR25 in Assessing Quality of Life of Prostate Cancer Patients Wei-Chu Chie 1, Chih-Chieh
More informationAnota et al. Health and Quality of Life Outcomes 2014, 12:32
Anota et al. Health and Quality of Life Outcomes 2014, 12:32 RESEARCH Open Access Item response theory and factor analysis as a mean to characterize occurrence of response shift in a longitudinal quality
More informationBinary Diagnostic Tests Two Independent Samples
Chapter 537 Binary Diagnostic Tests Two Independent Samples Introduction An important task in diagnostic medicine is to measure the accuracy of two diagnostic tests. This can be done by comparing summary
More informationKey words: social marketing, iron-folic acid, socioeconomic INTRODUCTION
December 2005: (II)S134 S138 Positive Impact of a Weekly Iron-Folic Acid Supplement Delivered with Social Marketing to Cambodian Women: Compliance, Participation, and Hemoglobin Levels Increase with Higher
More informationSystematic Inductive Method for Imputing Partial Missing Dates in Clinical Trials
Paper PO05 Systematic Inductive Method for Imputing Partial Missing Dates in Clinical Trials Ping Liu ABSTRACT In any phase of clinical trials, dates are very critical throughout the entire trial. However,
More informationTable of Contents. Plots. Essential Statistics for Nursing Research 1/12/2017
Essential Statistics for Nursing Research Kristen Carlin, MPH Seattle Nursing Research Workshop January 30, 2017 Table of Contents Plots Descriptive statistics Sample size/power Correlations Hypothesis
More informationQuality of Life and Survivorship:
Quality of Life and Survivorship: Implications for Future Ovarian Cancer Research and Care Lari Wenzel, PhD Professor of Medicine & Public Health Associate Director, Population Science and Cancer Control
More informationJune 30, Marlene H. Dortch Secretary Federal Communications Commission th Street, SW Washington, DC 20554
Jennie B. Chandra Senior Counsel, Federal Policy Windstream Communications, Inc. 1101 17 th Street, NW, Suite 802 Washington, DC 20036 (202) 223-7667 jennie.b.chandra@windstream.com June 30, 2011 Marlene
More informationSupporting Family Caregivers through Palliative Care
Supporting Family Caregivers through Palliative Care Betty Ferrell, PhD, RN, MA, FAAN, FPCN, CHPN Director and Professor Division of Nursing Research and Education City of Hope, Duarte CA Family caregivers
More informationGLOBAL HEALTH. PROMIS Pediatric Scale v1.0 Global Health 7 PROMIS Pediatric Scale v1.0 Global Health 7+2
GLOBAL HEALTH A brief guide to the PROMIS Global Health instruments: ADULT PEDIATRIC PARENT PROXY PROMIS Scale v1.0/1.1 Global Health* PROMIS Scale v1.2 Global Health PROMIS Scale v1.2 Global Mental 2a
More informationWhat makes Oncology special? Johanna MURSIC, Indication Programmer PhUSE congress Budapest, October 15 th 2012
What makes Oncology special? Johanna MURSIC, Indication Programmer PhUSE congress Budapest, October 15 th 2012 Disclaimer The opinions expressed in this presentation and on the following slides are solely
More informationThe Added Value of Analyzing Pooled Health-Related Quality of Life Data: A Review of the EORTC PROBE Initiative
JNCI J Natl Cancer Inst (2016) 108(5): djv391 doi:10.1093/jnci/djv391 First published online December 28, 2015 Review The Added Value of Analyzing Pooled Health-Related Quality of Life Data: A Review of
More informationLARYNGEAL CANCER IN EGYPT: QUALITY OF LIFE MEASUREMENT WITH DIFFERENT TREATMENT MODALITIES
ORIGINAL ARTICLE LARYNGEAL CANCER IN EGYPT: QUALITY OF LIFE MEASUREMENT WITH DIFFERENT TREATMENT MODALITIES Ossama A. Hamid, MD, 1 Lobna M. El Fiky, MD, 1 Medani M. Medani, MD, 1 Ayman AbdelHady, MBBCh,
More informationImpact of pre-treatment symptoms on survival after palliative radiotherapy An improved model to predict prognosis?
Impact of pre-treatment symptoms on survival after palliative radiotherapy An improved model to predict prognosis? Thomas André Ankill Kämpe 30.05.2016 MED 3950,-5 year thesis Profesjonsstudiet i medisin
More informationBEST PRACTICES FOR IMPLEMENTATION AND ANALYSIS OF PAIN SCALE PATIENT REPORTED OUTCOMES IN CLINICAL TRIALS
BEST PRACTICES FOR IMPLEMENTATION AND ANALYSIS OF PAIN SCALE PATIENT REPORTED OUTCOMES IN CLINICAL TRIALS Nan Shao, Ph.D. Director, Biostatistics Premier Research Group, Limited and Mark Jaros, Ph.D. Senior
More informationPharmaceutical Applications
Creating an Input Dataset to Produce Incidence and Exposure Adjusted Special Interest AE's Pushpa Saranadasa, Merck & Co., Inc. Abstract Most adverse event (AE) summary tables display the number of patients
More informationBuy full version here - for $7.00
This is a Sample version of the Irritable Bowel Syndrome Quality Of Life (IBS-QOL) - The full version of Irritable Bowel Syndrome - Quality Of Life (IBS-QOL) comes without sample watermark.. The full complete
More informationImproved Transparency in Key Operational Decisions in Real World Evidence
PharmaSUG 2018 - Paper RW-06 Improved Transparency in Key Operational Decisions in Real World Evidence Rebecca Levin, Irene Cosmatos, Jamie Reifsnyder United BioSource Corp. ABSTRACT The joint International
More informationCost-effectiveness of osimertinib (Tagrisso )
Cost-effectiveness of osimertinib (Tagrisso ) for the treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small-cell lung
More informationReview of Veterinary Epidemiologic Research by Dohoo, Martin, and Stryhn
The Stata Journal (2004) 4, Number 1, pp. 89 92 Review of Veterinary Epidemiologic Research by Dohoo, Martin, and Stryhn Laurent Audigé AO Foundation laurent.audige@aofoundation.org Abstract. The new book
More informationMultidimensional fatigue and its correlates in hospitalized advanced cancer patients
Chapter 5 Multidimensional fatigue and its correlates in hospitalized advanced cancer patients Michael Echtelda,b Saskia Teunissenc Jan Passchierb Susanne Claessena, Ronald de Wita Karin van der Rijta
More informationMath Workshop On-Line Tutorial Judi Manola Paul Catalano. Slide 1. Slide 3
Kinds of Numbers and Data First we re going to think about the kinds of numbers you will use in the problems you will encounter in your studies. Then we will expand a bit and think about kinds of data.
More informationScottish Medicines Consortium
Scottish Medicines Consortium temozolomide 5, 20, 100 and 250mg capsules (Temodal ) Schering Plough UK Ltd No. (244/06) New indication: for the treatment of newly diagnosed glioblastoma multiforme concomitantly
More informationThis was a multinational, multicenter study conducted at 14 sites in both the United States (US) and Europe (EU).
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. NAME OF SPONSOR/COMPANY: Genzyme Corporation,
More informationIntroduction to SPSS S0
Basic medical statistics for clinical and experimental research Introduction to SPSS S0 Katarzyna Jóźwiak k.jozwiak@nki.nl November 10, 2017 1/55 Introduction SPSS = Statistical Package for the Social
More informationCHL 5225 H Advanced Statistical Methods for Clinical Trials. CHL 5225 H The Language of Clinical Trials
CHL 5225 H Advanced Statistical Methods for Clinical Trials Two sources for course material 1. Electronic blackboard required readings 2. www.andywillan.com/chl5225h code of conduct course outline schedule
More information25. Two-way ANOVA. 25. Two-way ANOVA 371
25. Two-way ANOVA The Analysis of Variance seeks to identify sources of variability in data with when the data is partitioned into differentiated groups. In the prior section, we considered two sources
More informationVersion No. 7 Date: July Please send comments or suggestions on this glossary to
Impact Evaluation Glossary Version No. 7 Date: July 2012 Please send comments or suggestions on this glossary to 3ie@3ieimpact.org. Recommended citation: 3ie (2012) 3ie impact evaluation glossary. International
More informationNutritional Counselling, cancer Outcome and Quality of Life!
Nutritional Counselling, cancer Outcome and Quality of Life! Paula Ravasco p.ravasco@fm.ul.pt Unit of Nutrition and Metabolism, Institute of Molecular Medicine Faculty of Medicine of the University of
More informationMath Workshop On-Line Tutorial Judi Manola Paul Catalano
Math Workshop On-Line Tutorial Judi Manola Paul Catalano 1 Session 1 Kinds of Numbers and Data, Fractions, Negative Numbers, Rounding, Averaging, Properties of Real Numbers, Exponents and Square Roots,
More informationHealth-related quality of life a prospective cohort study in phase I oncology trial participants 1
Health-related quality of life a prospective cohort study in phase I oncology trial participants 1 28 August 2018 Diane (A.J.) van der Biessen 2, Wendy H. Oldenmenger, Peer G. van der Helm, Dennis Klein,
More informationList of Figures. List of Tables. Preface to the Second Edition. Preface to the First Edition
List of Figures List of Tables Preface to the Second Edition Preface to the First Edition xv xxv xxix xxxi 1 What Is R? 1 1.1 Introduction to R................................ 1 1.2 Downloading and Installing
More informationManagement of radiation-induced nausea and vomiting with palonosetron in patients with pre-existing emesis: a pilot study
Original Article Management of radiation-induced nausea and vomiting with palonosetron in patients with pre-existing emesis: a pilot study Vithusha Ganesh, Stephanie Chan, Liying Zhang, Leah Drost, Carlo
More informationQuality of Life After Adjuvant Intra-Arterial Chemotherapy and Radiotherapy Versus Surgery Alone in Resectable Pancreatic and Periampullary Cancer
Quality of Life After Adjuvant Intra-Arterial Chemotherapy and Radiotherapy Versus Surgery Alone in Resectable Pancreatic and Periampullary Cancer A Prospective Randomized Controlled Study Marjolein J.
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationBinary Diagnostic Tests Paired Samples
Chapter 536 Binary Diagnostic Tests Paired Samples Introduction An important task in diagnostic medicine is to measure the accuracy of two diagnostic tests. This can be done by comparing summary measures
More informationIn Woong Han 1, O Choel Kwon 1, Min Gu Oh 1, Yoo Shin Choi 2, and Seung Eun Lee 2. Departments of Surgery, Dongguk University College of Medicine 2
Effect of Rowachol on Prevention of Postcholecystectomy Syndrome after Laparoscopic Cholecystectomy - Prospective multicenter Randomized controlled trial- In Woong Han 1, O Choel Kwon 1, Min Gu Oh 1, Yoo
More informationClinicalTrials.gov a programmer s perspective
PhUSE 2009, Basel ClinicalTrials.gov a programmer s perspective Ralf Minkenberg Boehringer Ingelheim Pharma GmbH & Co. KG PhUSE 2009, Basel 1 Agenda ClinicalTrials.gov Basic Results disclosure Initial
More informationMEET MARY KISQALI PATIENT PROFILES
KISQALI PATIENT PROFILES MEET MARY Mary was recently diagnosed with HR+/HER2- metastatic breast cancer Review the data from the MONALEESA-2 trial to see how patients like Mary responded The patient profile
More informationHealth-Related Quality of Life in SCALOP, a Randomized Phase 2 Trial Comparing Chemoradiation Therapy Regimens in Locally Advanced Pancreatic Cancer
International Journal of Radiation Oncology biology physics www.redjournal.org Clinical Investigation Health-Related Quality of Life in SCALOP, a Randomized Phase 2 Trial Comparing Chemoradiation Therapy
More informationSection 6: Analysing Relationships Between Variables
6. 1 Analysing Relationships Between Variables Section 6: Analysing Relationships Between Variables Choosing a Technique The Crosstabs Procedure The Chi Square Test The Means Procedure The Correlations
More informationChronic Kidney Disease. Paul Cockwell Queen Elizabeth Hospital Birmingham
Chronic Kidney Disease Paul Cockwell Queen Elizabeth Hospital Birmingham Paradigms for chronic disease 1. Acute and chronic disease is closely linked 2. Stratify risk and tailor interventions around failure
More informationCover Page. The handle holds various files of this Leiden University dissertation
Cover Page The handle http://hdl.handle.net/1887/46692 holds various files of this Leiden University dissertation Author: Zanten, Henriëtte van Title: Oxygen titration and compliance with targeting oxygen
More informationMapping QLQ-C30, HAQ, and MSIS-29 on EQ-5D
HEALTH-RELATED QUALITY OF LIFE Mapping QLQ-C30, HAQ, and MSIS-29 on EQ-5D Matthijs M. Versteegh, MA, Annemieke Leunis, MSc, Jolanda J. Luime, PhD, Mike Boggild, MD, MRCP, Carin A. Uyl-de Groot, PhD, Elly
More informationFeasibility Evaluation of a Novel Ultrasonic Method for Prosthetic Control ECE-492/3 Senior Design Project Fall 2011
Feasibility Evaluation of a Novel Ultrasonic Method for Prosthetic Control ECE-492/3 Senior Design Project Fall 2011 Electrical and Computer Engineering Department Volgenau School of Engineering George
More informationRESPONSE (NCT )
Changes in Quality of Life and Disease-Related Symptoms in Patients With Polycythemia Vera Receiving Ruxolitinib or Best Available Therapy: RESPONSE Trial Results Abstract #709 Mesa R, Verstovsek S, Kiladjian
More informationDifferences between Cancer Patients Symptoms Reported by Themselves and in Medical Records
Differences between Cancer Patients Symptoms Reported by Themselves and in Medical Records Ana Joaquim 1, Sandra Custódio 1, Alexandra Oliveira 2,3,4 & Francisco Luís Pimentel 2,3,4,5 1 Oncology Department,
More informationC++ in the Lab. Lab Manual to Accompany C++ How to Program, Fourth Edition. H. M. Deitel Deitel & Associates, Inc.
C++ in the Lab Lab Manual to Accompany C++ How to Program, Fourth Edition H. M. Deitel Deitel & Associates, Inc. P. J. Deitel Deitel & Associates, Inc. T. R. Nieto Deitel & Associates, Inc. Prentice Hall
More informationHealth-related quality of life in long-term survivors of unresectable locally advanced non-small cell lung cancer
Ran et al. Radiation Oncology (2017) 12:195 DOI 10.1186/s13014-017-0909-6 RESEARCH Open Access Health-related quality of life in long-term survivors of unresectable locally advanced non-small cell lung
More informationThe Relationship Between Cancer-Related Fatigue and Patient Satisfaction with Quality of Life in Cancer
40 Journal of Pain and Symptom Management Vol. 34 No. 1 July 2007 Original Article The Relationship Between Cancer-Related Fatigue and Patient Satisfaction with Quality of Life in Cancer Digant Gupta,
More informationReliability and validity of the Cancer Therapy Satisfaction Questionnaire in lung cancer
Qual Life Res (2016) 25:71 80 DOI 10.1007/s11136-015-1062-z Reliability and validity of the Cancer Therapy Satisfaction Questionnaire in lung cancer K. Cheung 1,4 M. de Mol 2,3 S. Visser 1,2,3 B. L. Den
More informationFunctional Status and Health-Related Quality of Life in Patients with Primary Intracranial Tumour
ORIGINAL ARTICLE Functional Status and Health-Related Quality of Life in Patients with Primary Intracranial Tumour Ooi Ai Lee, MRehab Med, Mazlina Mazlan, MBBS, MRehabMed Department of Rehabilitation Medicine,
More informationDr. Atsuo Yanagisawa President Japanese College of Intravenous Therapy International Society for Orthomolecular Medicine
Intravenous Vitamin C Therapy In Japan Dr. Atsuo Yanagisawa President Japanese College of Intravenous Therapy International Society for Orthomolecular Medicine 1 Dr. Atsuo Yanagisawa, MD, PhD Director
More informationIMPACT OF PATIENT COUNSELING BY CLINICAL PHARMACIST ON QUALITY OF LIFE IN CANCER PATIENTS
WORLD JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES Chowdary et al. SJIF Impact Factor 6.647 Volume 6, Issue 4, 1093-1099 Research Article ISSN 2278 4357 IMPACT OF PATIENT COUNSELING BY CLINICAL PHARMACIST
More informationHow to select an age-friendly fitness facility
How to select an age-friendly fitness facility How to select an age-friendly fitness facility The International Council on Active Aging (ICAA), the world s largest senior fitness association, has created
More informationPROSPERO International prospective register of systematic reviews
PROSPERO International prospective register of systematic reviews The effect of probiotics on functional constipation: a systematic review of randomised controlled trials EIRINI DIMIDI, STEPHANOS CHRISTODOULIDES,
More informationPreoperative Quality of Life in Patients with Gastric Cancer
pissn : 2093-582X, eissn : 2093-5641 J Gastric Cancer 2015;15(2):121-126 http://dx.doi.org/10.5230/jgc.2015.15.2.121 Original Article Preoperative Quality of Life in Patients with Gastric Cancer Hyoam
More informationQuality of life measures (EORTC QLQ-C30 and SF-36) as predictors of survival in palliative colorectal and lung cancer patients
Palliative and Supportive Care (2009), 7, 289 297. Copyright # Cambridge University Press, 2009 1478-9515/09 $20.00 doi:10.1017/s1478951509990216 Quality of life measures (EORTC QLQ-C30 and SF-36) as predictors
More informationAuthor Block M. Fisch, J. W. Lee, J. Manola, L. Wagner, V. Chang, P. Gilman, K. Lear, L. Baez, C. Cleeland University of Texas M.D. Anderson Cancer Ce
Survey of disease and treatment-related t t related symptoms in outpatients with invasive i cancer of the breast, prostate, lung, or colon/rectum (E2Z02, the SOAPP study, Abst # 9619) Michael J. Fisch,
More informationPROGRAMMER S SAFETY KIT: Important Points to Remember While Programming or Validating Safety Tables
PharmaSUG 2012 - Paper IB09 PROGRAMMER S SAFETY KIT: Important Points to Remember While Programming or Validating Safety Tables Sneha Sarmukadam, Statistical Programmer, PharmaNet/i3, Pune, India Sandeep
More informationADVANCED VBA FOR PROJECT FINANCE Near Future Ltd. Registration no
ADVANCED VBA FOR PROJECT FINANCE f i n a n c i a l f o r e c a s t i n G 2017 Near Future Ltd. Registration no. 10321258 www.nearfuturefinance.com info@nearfuturefinance.com COURSE OVERVIEW This course
More informationInvestigating the performance of a CAD x scheme for mammography in specific BIRADS categories
Investigating the performance of a CAD x scheme for mammography in specific BIRADS categories Andreadis I., Nikita K. Department of Electrical and Computer Engineering National Technical University of
More informationOne-Way Independent ANOVA
One-Way Independent ANOVA Analysis of Variance (ANOVA) is a common and robust statistical test that you can use to compare the mean scores collected from different conditions or groups in an experiment.
More informationPalliative Care: Expanding the Role Throughout the Patient s Journey. Dr. Robert Sauls Regional Lead for Palliative Care
Palliative Care: Expanding the Role Throughout the Patient s Journey Dr. Robert Sauls Regional Lead for Palliative Care 1 Faculty/Presenter Disclosure Faculty: Dr. Robert Sauls MD, with the Mississauga
More informationJosh is JB s brother and caregiver.
PUT GBM ON PAUSE PUT LIFE ON PLAY Josh is JB s brother and caregiver. JB is an Optune user. OPTUNE + TMZ HAS BEEN PROVEN TO PROVIDE LONG-TERM QUALITY SURVIVAL TO PATIENTS WITH NEWLY DIAGNOSED GBM1,2,*
More informationQuality of life across chemotherapy lines in patients with advanced colorectal cancer: a prospective single-center observational study
Quality of life across chemotherapy lines in patients with advanced colorectal cancer: a prospective single-center observational study Beate Mayrbäurl, Johannes M. Giesinger, Sonja Burgstaller, Gudrun
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objective: Primary Outcome/Efficacy Variable:
Studies listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationImproving Informed Consent to Clinical Research. Charles W. Lidz Ph.D.
Improving Informed Consent to Clinical Research Charles W. Lidz Ph.D. Housekeeping Items Please note that this broadcast is being recorded and will be available soon for viewing on SPARC s website. Please
More informationINTERMEZZO ONCOQUEST: A TOUCH-SCREEN COMPUTER ASSISTED SYSTEM TO MONITOR HEALTH RELATED QUALITY OF LIFE VIA PATIENT REPORTED OUTCOME MEASURES
24 INTERMEZZO ONCOQUEST INTERMEZZO ONCOQUEST: A TOUCH-SCREEN COMPUTER ASSISTED SYSTEM TO MONITOR HEALTH RELATED QUALITY OF LIFE VIA PATIENT REPORTED OUTCOME MEASURES 26 INTERMEZZO In 2006, the Department
More informationAn Introduction to Modern Econometrics Using Stata
An Introduction to Modern Econometrics Using Stata CHRISTOPHER F. BAUM Department of Economics Boston College A Stata Press Publication StataCorp LP College Station, Texas Contents Illustrations Preface
More information1. Introduction This updated guidance sets out the preferred way for scoring and presenting the UW-QOL.
University of Washington Quality of Life Questionnaire (UW-QOL v4 and v4.1) Guidance for scoring and presentation Derek Lowe & Simon N Rogers (Updated 21-1-2018) 1. Introduction This updated guidance sets
More informationSTA 3024 Spring 2013 EXAM 3 Test Form Code A UF ID #
STA 3024 Spring 2013 Name EXAM 3 Test Form Code A UF ID # Instructions: This exam contains 34 Multiple Choice questions. Each question is worth 3 points, for a total of 102 points (there are TWO bonus
More informationBRL /RSD-101C0D/1/CPMS-704. Report Synopsis
Report Synopsis Study Title: A Randomized, Multicenter, 10-Week, Double-Blind, Placebo- Controlled, Flexible-Dose Study to Evaluate the Efficacy and Safety of Paroxetine in Children and Adolescents with
More informationTable of Contents Foreword 9 Stay Informed 9 Introduction to Visual Steps 10 What You Will Need 10 Basic Knowledge 11 How to Use This Book
Table of Contents Foreword... 9 Stay Informed... 9 Introduction to Visual Steps... 10 What You Will Need... 10 Basic Knowledge... 11 How to Use This Book... 11 The Screenshots... 12 The Website and Supplementary
More informationImprovement in Pittsburgh Symptom Score Index After Initiation of Peritoneal Dialysis
Advances in Peritoneal Dialysis, Vol. 24, 2008 Matthew J. Novak, 1 Heena Sheth, 2 Filitsa H. Bender, 1 Linda Fried, 1,3 Beth Piraino 1 Improvement in Pittsburgh Symptom Score Index After Initiation of
More information